Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


GlaxoSmithKline, Vir Biotech Report Primary Endpoint Was Met In COMET-TAIL Phase 3 Trial In Candidate For Treatment Of Intramuscular Admin. Of Sotrovimab


Benzinga | Nov 12, 2021 07:15AM EST

GlaxoSmithKline, Vir Biotech Report Primary Endpoint Was Met In COMET-TAIL Phase 3 Trial In Candidate For Treatment Of Intramuscular Admin. Of Sotrovimab

-Reuters-Reuters






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC